Trial Profile
An open-label, single-dose, non-randomized, balanced design three-way cross-over study to examine the variability in absorption of GSK561679 using gamma scintigraphy, PillCam SB capsule and the acoustic vest in healthy males volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Verucerfont (Primary) ; Verucerfont
- Indications Depressive disorders; Irritable bowel syndrome; Social phobia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 24 Apr 2008 Status changed from initiated to completed according to ClinicalTrials.gov.
- 16 Oct 2007 New trial record.